Evidence map›Paper›PMID 39599877›Full record

Trial reportViruses2024

A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study.

Alison D Marshall, Anna Conway, Evan B Cunningham, Heather Valerio, David Silk, Maryam Alavi, Shane Tillakeratne, Alexandra Wade, Thao Lam, Krista Zohrab and 9 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alison D MarshallThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0001-7476-7894
Anna ConwayThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Evan B CunninghamThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Heather ValerioThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
David SilkThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Maryam AlaviThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Shane TillakeratneThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Alexandra WadeDrug and Alcohol Clinical Services, Mid North Coast Local Health District, Kempsey, NSW 2440, Australia.
Thao LamDrug and Alcohol Clinical Services, Western Sydney Local Health District, Sydney, NSW 2770, Australia.
Krista ZohrabLismore Liver Clinic, Mid North Coast Local Health District, Lismore, NSW 2480, Australia.
Adrian DunlopDrug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW 2302, Australia.ORCID 0000-0003-2394-5966
Craig ConnellyNorth Metro Community Alcohol & Drug Service, Joondalup, WA 6027, Australia.
Victoria CockDrug and Alcohol Services South Australia (DASSA), Adelaide, SA 5069, Australia.ORCID 0000-0002-2014-5077
Carina BurnsDrug and Alcohol Clinical Services, South Western Sydney Local Health District, Sydney, NSW 2170, Australia.
Charles HendersonNSW Users and AIDS Association, Sydney, NSW 2010, Australia.
Michael ChristmassNational Drug Research Institute, Curtin University, Perth, WA 6102, Australia.ORCID 0000-0001-9782-1849
Gregory J DoreThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-4741-2622
Jason GrebelyThe Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.ORCID 0000-0002-1833-2017
ETHOS Engage Study Group

Funding

National Health & Medical Research Council (NHMRC) Partnership project grant 1103165
6 · The paper itself

Abstract

The primary aim of this study was to establish the feasibility of implementing a larger RCT designed to evaluate the effect of financial incentives on HCV treatment initiation among persons receiving opioid agonist therapy and/or who have injected drugs in the prior six months. ETHOS Engage is an observational cohort of participants recruited from drug treatment and needle and syringe programs in Australia. Among 11 drug and alcohol clinics, participants who were HCV RNA-positive were randomized (1:1) to receive standard of care or a AUD $60 gift card at treatment initiation. Regarding feasibility, 100% (57/57) of eligible participants enrolled to take part. Twenty-eight participants were randomised to the financial incentive arm (AUD $60 gift card) plus standard of care and 29 participants to the standard of care arm. In this pilot RCT (n = 57), median age was 42 years (IQR 37-49), 63% were male (n = 36), 35% Indigenous (n = 20) and 36% (n = 21) reported injecting drugs daily in the past month. Twelve weeks post-study enrolment, 11 (39%) participants in the financial incentive arm and 17 (59%) participants in the standard of care arm initiated HCV treatment. Findings indicate high feasibility among people who inject drugs to be randomised to receive financial incentives to initiate HCV treatment.

Indexed as

Hepatitis CMotivationSubstance Abuse, IntravenousAdultAntiviral AgentsAustraliaFemaleHepacivirusHumansMaleMiddle AgedPilot ProjectsAntiviral Agentscontingency managementfinancial incentivehepatitis C virusrandomised controlled trialtreatment

Identifiers

PMID39599877
PMCPMC11599082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.